Canada: Canadian Patent Appeal Board Adopts A New Approach To Attack Patents For Lack Of Utility

Last Updated: January 25 2018
Article by Erica Lowthers

In order for a factual basis and/or sound line of reasoning for predicted utility to be considered sufficiently disclosed in the common general knowledge and, therefore, not required to be disclosed in the specification, the PAB has taken the position that the subject matter must be "generally known and accepted without question by the bulk of those who are engaged in the particular art."

In Canada, as in most other jurisdictions, a claimed invention must be useful; this is usually a minimal requirement that is easy to meet. In Canada, when utility is not demonstrated through examples in the specification, it must be soundly predicted as of the Canadian filing date.

It is well-accepted that sound prediction requires three components, as set out in Apotex Inc. v. Wellcome Foundation Ltd., 2002 SCC 77 (paragraph [70]):

Firstly ... there must be a factual basis for the prediction ... Secondly, the inventor must have at the date of the patent application an articulable and 'sound' line of reasoning from which the desired result can be inferred from the factual basis ... Thirdly, there must be proper disclosure.

The precise ambit of "proper disclosure" has been litigated extensively with respect to whether the factual basis and sound line of reasoning must be found in the specification. Although perhaps not entirely settled, the general consensus is that these components must be disclosed in the specification unless they form part of the common general knowledge.

The last 15 years have seen a heightened requirement for usefulness in Canada, where any statements of utility in the description of a patent would be construed to determine whether these amounted to a promise of utility. If such statements were construed as promises, then those promises acted as the yardstick against which the utility of the claims would be measured. This came to be known as the "Promise Doctrine."

A landmark decision by the Supreme Court of Canada (AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36; blogged about here), struck down the Promise Doctrine as being "punitive," "antagonistic to the bargain on which patent law is based," and "not good law." This decision was celebrated by patentees and patent agents alike. Despite this, sound prediction remains good law and many of us in the profession have been watching decisions related to utility to see if the Courts or the Canadian Patent Appeal Board (PAB) might have an appetite for sustaining attacks based upon lack of utility. The PAB, it seems, does have such an appetite.

In Commissioner's Decision No. 1437, Canadian Patent Application No. 2,454,678 was refused for lack of utility. Claim 1 reads as follows:

A method for the adaptation of bacteria for use in the leaching of ores and concentrates, the method characterised by the steps of:

a) Obtaining samples of bacteria exhibiting salt tolerance;

b) Combining the bacterial samples from step a) with a stock bacterial culture known to have the ability to oxidise sulphide minerals; and

c) Growing the combined culture of step b) over time in saline conditions to produce an adapted stock bacterial culture that expresses salt tolerance in addition to its ability to oxidise sulphide minerals.

The PAB stated, in paragraph [74], that:

Claims 1 and 4 assert the utility to be the production of "an adapted stock bacterial culture that expresses salt tolerance in addition to its ability to oxidise sulphide minerals." We are of the view that the person skilled in the art would understand this to mean that the defined methods will result in an adapted stock bacterial culture that is both "salt tolerant" and able to oxidize sulphide minerals.

Rightly so, the PAB steered well clear of arguing that specific promises were not met and mentioned the Supreme Court's AstraZeneca decision only once. Instead, the PAB focused on whether there was a proper disclosure of the factual basis and sound line of reasoning for the construed utility in the specification and, perhaps not surprisingly, found that there was not.

Therefore, the PAB discussed in detail the definition of "common general knowledge" and whether the factual basis and sound line of reasoning could be found there. In doing so, the PAB cited Uponor AB v. Heatlink Group Inc., 2016 FC 320, which itself cited Eli Lilly and Company v. Apotex Inc., 2009 FC 991, which in turn cited several earlier cases relating to this issue. Although these cases related to common general knowledge and how it may differ from a citable reference with respect to novelty and obviousness, the PAB applied them without much explanation as to how the common general knowledge relates to the disclosure of a factual basis and sound line of reasoning for assessing sound prediction of utility.

The PAB identified in these cases the statement that, for something to be considered common general knowledge, it must be "generally known and accepted without question by the bulk of those who are engaged in the particular art." The PAB argued that since there is no evidence that the factual basis and sound line of reasoning were "accepted without question," they could not be considered part of the common general knowledge.

Interestingly, however, Eli Lilly had in fact affirmed a tempering of the definition that common general knowledge must be "generally accepted without question" and instead held that it must, rather, be "generally regarded as a good basis for further action." This is a lower bar than that which was held by the PAB and was not addressed in the decision.

Moreover, the claims in question are method claims and their language appears to guarantee that only those combined cultures that "produce an adapted stock bacterial culture that expresses salt tolerance in addition to its ability to oxidise sulphide minerals" would fall within the scope of the claims. Utility should truly be a non-issue here, since any combined culture that does not have the recited utility is excluded from the scope of the claims and only useful cultures are explicitly claimed.

Furthermore, the PAB seems to be asserting that the utility here relates to whether the invention could be made, rather than whether the invention in its full scope, would work. This is misguided, as explained in Laboratoires Servier, Adir, Oril Industries, Servier Canada Inc. v. Apotex Inc., 2008 FC 825 (affirmed, 2009 FCA 222).

Hopefully this case will be appealed so we can see further debate on these issues and guidance from the Federal Court. Absent such guidance, this will likely be a new path that Examiners in Canada will be following. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions